Brief: Sonnet’S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer
04/04/2025 14:03
April 4 (Reuters) - Sonnet Biotherapeutics Holdings Inc SONN.O: SONNET’S SON-1010 DEMONSTRATES A STRONG SAFETY PROFILE IN COMBINATION WITH ATEZOLIZUMAB FOR TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER, INCLUDING A PARTIAL RESPONSE AT THE HIGHEST DOSE SONNET BIOTHERAPEUTICS HOLDINGS INC - TOPLINE SAFETY DATA SUGGEST CLINICAL BENEFIT OF SON-1010 WITH ATEZOLIZUMAB Source text: ID:nGNX6KdhK7 Further company coverage: SONN.O (((( Reuters.briefs@thomsonreuters.com ;));))